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Combined doseAbstract Background: Adaptive response has been well studied by employing physical and chem-
ical agents in normal test systems, whereas in diseased conditions very little data are available.
Aim of the study: To know the presence or absence of adaptive response in diseased condition,
alkylating agents such as EMS or MMS have been employed in diabetic mouse.
Material and methods: To induce diabetes, mice were injected with 180 mg/kg body weight of
Stz. Diabetic mice were treated with conditioning (100 mg/kg body weight of EMS or 40 mg/kg
body weight of MMS), challenging (300 mg/kg body weight of EMS or 160 mg/kg body weight
of MMS) and combined doses of EMS or MMS with 8 h time lag. Parallelly controls were main-
tained. Mice were sacriﬁced at 24 or 48 or 72 h RTs. Bone marrow was extracted and slides were
prepared by a routine air dry technique by Evans et al. (1964) to analyze the chromosomal aberra-
tions.
Results: The results show that both the alkylating agents induced exclusively chromatid type of
aberrations in both diabetic and non diabetic mice, but it is to be underlined that MMS is a more
potent inducer of aberrations than EMS. Eventhough, combined treatment of EMS or MMS
induced signiﬁcantly less chromosomal breaks compared to challenging treatment (p< 0.05) in dia-
betic mice, EMS induced 40% reduction of breaks, compared to 51.74% by MMS at 24 h RT. This
is true to other tested RTs.
Conclusion: (1) Methylating agents are a more effective inducer of adaptive response than ethy-
lating agents in diabetic mouse. (2) Further, it is interesting to note that the percentage reduction of
chromosomal breaks in diabetics is comparatively much less than in non diabetic mouse, inferring
that there is variation in adaptive response between diseased and non diseased condition.
 2015 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1 Yield of chromosomal breaks induced after different
treatment schedules of EMS and (b) MMS. Note: values with
different superscripts are signiﬁcantly different from one another
(p< 0.05) according to Duncan Post hoc test.
202 B.B.D. Khalandar, V. Vasudev1. Introduction
DNA is being continuously exposed to endogenous and exoge-
nous agents and each cell receives about thousands of DNA
lesions per day [1]. These lesions, commonly include base mod-
iﬁcations, single and double strand breaks, DNA–protein cross
links, and base free sites [2], if not repaired, are proved to be
lethal to the cells. To overcome this, cells are well equipped
with different repair mechanisms such as photoreactivation
[3], excision repair [2], mismatch repair [4], homologous recom-
bination [5], non homologous end joining [6] and inducible
repair mechanisms [7]. One such inducible repair mechanism
is SOS, an error prone repair mechanism [8] and the other is
adaptive response, an error free repair mechanism [9]. Samson
and Cairns, showed that Escherichia coli cells were resistant to
killing and mutagenic effect of toxic treatment of N-methyl,
N-nitro-N-nitrosoguanidine (MNNG), which were pre treated
with a sub toxic dose of the same agent. Later extensive work
has been carried out in both prokaryotes and eukaryotes using
physical [cf. 10] and chemical [cf. 11] agents. Mahadimane and
Vasudev [12] reported the presence of adaptive response in
in vivo ehrlich ascites tumor cells, a cancerous condition.
However, adaptive response has not been worked out in vari-
ous diseased conditions such as Alzheimer, arthritis, asthma,
bronchitis and diabetes, which require immediate attention.
Diabetes is a multifarious disease and 7th leading cause of
death around the world. About 387 million people are suffering
from diabetes around the world and expected to reach 592 million
by the end of 2035 (International Diabetic Federation, 2014).
These diabetic patients are exposed to varied chemical agents/
drugs, which might lead to serious disorders. In our previous
study, it has been demonstrated that EMS and MMS induced
less number of chromosomal aberrations in diabetic compared
to non diabetic mice [13]. As has been said, there is increasing
trend of diabetic patients around the world, who are being
exposed to various chemicals including alkylating agents.
There is a necessity to get the picture of adaptive response in
diabetic systems. In order to know the presence or absence
of adaptive response in diabetic condition, the present investi-
gation has been carried out by employing EMS or MMS as
alkylating agents.
2. Materials and methods
Mono functional alkylating agents, methyl methanesulfonate
(MMS) (CAS number 66-27-3), and ethyl methanesulfonate
(EMS) (CAS number 62-50-0) were obtained from Sigma
Co., St. Louis, MO, USA, and colchicine (CAS number
64-86-8) was obtained from Himedia, Pvt. Ltd., Mumbai,
India. Giemsa stain and other chemicals of analytical grade
were commercially available. EMS and MMS were dissolved
in 0.9% NaCl to obtain the required concentrations. Freshly
prepared solutions of these agents were used each time. From
the dose effect relationship study by Khalandar and Vasudev
[13], a dose which induced few chromosomal aberrations and
a dose that produced high aberrations were selected as
conditioning and challenging doses respectively. Accordingly
for EMS 100 mg/kg body weight as the conditioning and
300 mg/kg body weight as challenging dose and for MMS
40 mg/kg body weight and 160 mg/kg body weight as condi-
tioning and challenging dose were selected respectively.2.1. Animals
Male Swiss albino mice weighing 25–30 g of 6–8 weeks old were
used and housed in polypropylene cages, provided with stan-
dard feed pellets and water ad libitum under 12 h of light/dark
cycle. The study was approved by the Institutional Animal
Ethics Committee and the work was carried out in accordance
with The Code of Ethics of The World Medical Association
(Declaration of Helsinki) for experiments in animals.
2.2. Induction of diabetes in mouse
Diabetes was induced by injecting a single intra peritoneal dose
of Streptozotocin (180 mg/kg body weight) (freshly prepared
in 0.1 M citrate buffer pH 4.5) as described by Yanardag
et al. [14]. The control mice were given 0.5 ml of citrate buffer.
Prior to administration, mice were fasted for 4 h but were
given water ad libitum. Animals were kept under observation
for 5 days following administration and blood glucose concen-
tration was measured by SD check glucometer, Japan. On the
ﬁfth day mice with blood glucose levels above 300 mg/dl and
below 400 mg/dl were used in the present studies as type I
diabetic mouse [15].
2.3. Treatment schedule
Diabetic and non diabetic mice were grouped from A to D
for MMS and EMS, each group consisting of 3 animals.
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Cytogenetic adaptive response 203Diabetic and non diabetic mice were injected with 0.5 ml
saline containing conditioning dose of 100 or 40 mg/kg body
weight and challenging dose of 300 or 160 mg/kg body
weight of EMS or MMS respectively. For adaptive response
the animals were injected with conditioning dose of EMS
(100 mg/kg body weight) or MMS (40 mg/kg body weight)
and after 8 h animals were injected with respective challeng-
ing dose (EMS-300 mg/kg body weight and MMS-160 mg/kg
body weight). The control animals received only 0.5 ml of
saline. Animals were sacriﬁced at 24, 48 and 72 h recovery
times (RTs).
2.4. Mitotic chromosome preparation
90 min before killing, the treated animals were injected
intraperitoneally with 0.5 ml of 0.05% colchicine. Bone mar-
row was extracted and slides were prepared by a routine air
dry technique [16]. These air-dried slides were coded and
stained with 4% Giemsa for 20–30 min. Non-overlapping
metaphase plates were scored for chromosomal aberrations
such as chromatid breaks, chromatid exchanges, intra-
chromatid deletions, triradials, chromosome breaks,
dicentrics, rings, and minutes. 100 well spread metaphase
plates were scored for each animal and experiments were
repeated thrice.
2.5. Statistical analyses
The data were expressed as mean ± S.E and compared using a
one way analysis of variance (ANOVA). Comparisons among
groups were made according to Duncun’s post hoc comparison
test.T
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.3. Results
The conditioning dose of EMS or MMS resulted in signiﬁcant
aberrations and on the other hand, maximum number of aber-
rations were noticed when challenging dose of said agents was
given to diabetic mouse (p< 0.05) compared to controls. The
same results were observed at all RTs tested (Tables 1–3).
61.56% of chromatid aberrations which were the majority,
was observed when the challenging dose of MMS was given
to diabetic mouse compared to 11.11% chromosome aberra-
tions at 24 h RT. The same is true for other treatments and
other RTs tested (Tables 2–5). However, when the condition-
ing and challenging dose were given together (combined treat-
ment) to diabetic mouse, the results have shown that there is
signiﬁcant reduction in the number of total chromosomal aber-
rations at all RTs of the tested agents (Tables 1–5) compared
to challenging dose (p< 0.05).
When the chromosomal aberrations were converted to
chromosomal breaks and when individual treatments were
contrasted, the results have revealed that challenging dose of
EMS in diabetic mouse induced 76.55 ± 3.58% breaks
whereas the combined dose produced 56.77 ± 3.87% breaks
at 24 h RT, which is signiﬁcant (p< 0.05) (Fig. 1(a)). The
same is observed at different RTs and treatments (Fig. 1
(a) and (b)). Tables 6 and 7 gives the percentage reduction of
chromosomal breaks in EMS or MMS treated diabetic mouse
at different RTs tested compared to additive effects.
204 B.B.D. Khalandar, V. Vasudev4. Discussion
DNA is the target for all alkylating agents which induce
lesions that in turn result in micronucleus [17,18], sister chro-
matid exchanges [19,20], intra chromatid deletions, rings, iso
chromatid breaks and chromatid breaks [cf. [21]] in varied test
systems. EMS and MMS, the monofunctional alkylating
agents, used in the present investigation induced a more chro-
matid type of aberrations than chromosomal aberrations in
both diabetic and non diabetic mouse system (Tables 1–5).
Thus, proving that, these agents are S-dependent agents in dis-
eased condition also. These observations are in agreement with
earlier ﬁndings of Rao and Natarajan in Vacia faba [22], Vogel
and Natarajan in Drosophila [23], Mahmood in non diabetic
mouse [21], Harish et al. in human lymphocytes [24] and
Mahadimane and Vasudev in in vivo ascites cells [12].
Chromosomal aberrations’ study revealed that 35 mg/kg
body weight of MMS is sufﬁcient to induce 16.11% of chro-
mosomal aberration, whereas, 100 mg/kg body weight of
EMS induced almost similar number 17.33% aberrations,
which is very high compared to the dose of MMS (Tables 1
and 3). For this reason it can be said that MMS is a strong
inducer of chromosomal aberrations compared to EMS. Sim-
ilarly Rao and Natarajan using Vicia faba [21], Vogel and
Natarajan using Drosophila [22], Mahmood et al. using mouse
[25], and Harish et al. using human lymphocytes [24] have
shown that methylating agents are more potent inducer of
aberrations than ethylating agents.
Since the ﬁrst evidence of the presence of adaptive response
in E. coli by Samson and Cairns [9] using MNNG, extensive
research has been carried out by a number of scientists
[10,26–30] in different test systems and generalized the discov-
ery that pre treatment with conditioning dose protects DNA
damages induced by subsequent challenge dose.Table 2 Percentage frequency of chromosomal aberrations (mean ±
EMS in non diabetic and diabetic mice bone marrow cells recovered
Recovery time in h Treatments Chromos
Chromat
Control Non diabetic 2.22 ± 0
Diabetic 2.33 ± 0
48 Conditioning Non diabetic 18.33 ± 1
Diabetic 11.00 ± 1
Challenging Non diabetic 70.67 ± 6
Diabetic 46.67 ± 3
Combined Non diabetic 53.33 ± 3
Diabetic 36.67 ± 3
72 Control Non diabetic 2.22 ± 0
Diabetic 2.56 ± 0
Conditioning Non diabetic 15.78 ± 1
Diabetic 10.33 ± 2
Challenging Non diabetic 58.67 ± 6
Diabetic 42.00 ± 2
Combined Non diabetic 45.33 ± 2
Diabetic 32.00 ± 2
Note: pooled data from three independent experiments; 900 cells were an
with same superscripts are not signiﬁcant (p> 0.05); values with differen
according to Duncan Post hoc test. a–f have been used to distinguish difEventhough, using the said agents, adaptive response has
been well documented in varied test systems employing various
end points in normal cells [21,24,12]. To the best of our
knowledge there are no data on adaptive response in diseased
conditions such as diabetes. To get the diabetic conditioned
animals in the present investigations, mouse was injected
with Streptozotocin and to analyze adaptive response the
prerequisite is the selection of doses namely conditioning and
challenging. These doses of EMS or MMS were selected based
on the work of Khalandar and Vasudev [13] and the results
have revealed that both these agents induced signiﬁcant
chromosomal aberrations in diabetic mouse (Tables 1–5).
These ﬁndings further validate the results of earlier works
[12] cf. [31]]. Mahmood et al. [25] demonstrated that 8 h time
lag between conditioning and challenging treatments commen-
surate the peak level of repair enzymes. The same time lag used
in the present investigations revealed the signiﬁcant decrease in
chromosomal aberrations with EMS or MMS conditioning
(Tables 1–5). On par with this Mahadimane and Vasudev
[12] with the above said preconditioning with EMS or MMS,
demonstrated the presence of adaptive response using the same
end point in in vivo ascite tumor cells. Similarly, reduction in
frequency of micronuclei was reported by Assadi et al. [32],
when human lymphocytes were irradiated with conditioning
dose (5 cGy) before challenging dose (2 Gy) of gamma radiations
compared to challenging alone. Further the same phenomenon
was studied in Drosophila [33], Poecilocerus pictus [29] and
Chinese hamster cells [26].
There is a strong evidence to prove that methylating agents
are a more effective inducer of adaptive response than ethylat-
ing agents in normal cells [34,35,25,36]. Our results also prove
the same in that, MMS reduced the chromosomal breaks to
51.74% compared to 40% with EMS in diabetic mouse at
24 h RT. Similar results were observed at tested RTs (Tables 1–5).SE) induced by conditioning, challenging and combined doses of
after 48 h and 72 h.
omal aberrations Total aberrations
id aberrations Chromosome aberrations
.31 0 2.22 ± 0.31a
.29 0.11 ± 0.11 2.44 ± 0.4a
.57 0.55 ± 0.40 18.89 ± 0.80b
.22 1.11 ± 0.63 12.11 ± 1.5b
.25 7.22 ± 1.56 77.89 ± 5.79e
.96 6.56 ± 1.43 53.23 ± 3.37c
.86 4.45 ± 1.78 57.78 ± 2.48d
.67 5.00 ± 5.0 41.66 ± 3.18f
.31 0 2.22 ± 0.31a
.44 0.11 ± 0.11 2.67 ± 0.51a
.46 0.55 ± 0.4 16.33 ± 0.19b
.08 1.00 ± 0.67 11.33 ± 2.60b
.41 7.11 ± 1.8 65.78 ± 4.56e
.92 4.34 ± 0.63 46.33 ± 3.06c
.1 3.78 ± 1.84 49.11 ± 2.99c
.65 3.33 ± 1.61 35.33 ± 2.08d
alyzed per treatment; 3 animals were used for each treatment. Values
t superscripts are signiﬁcantly different from one another (p< 0.05)
ferent values with statistical signiﬁcance.
Table 3 Percentage frequency of chromosomal aberrations (mean ± SE) induced by conditioning, challenging and combined doses of
MMS in non diabetic and diabetic mice bone marrow cells recovered after 24 h.
Treatments Chromosomal aberrations Total aberrations
Chromatid aberrations Chromosome aberrations
Control Non diabetic 2.23 ± 0.30 0 2.22 ± 0.22a
Diabetic 2.33 ± 0.29 0.11 ± 0.11 2.45 ± 0.4a
Conditioning Non diabetic 20.78 ± 2.37 1.22 ± 0.40 22.00 ± 2.6b
Diabetic 14.89 ± 1.73 1.22 ± 0.40 16.11 ± 0.67b
Challenging Non diabetic 87.45 ± 3.12 16.45 ± 2.68 103.89 ± 2.61c
Diabetic 61.56 ± 3.53 11.11 ± 2.74 72.67 ± 2.00d
Combined Non diabetic 46.67 ± 2.41 6.22 ± 2.75 52.89 ± 3.56e
Diabetic 41.33 ± 2.40 4.11 ± 1.44 45.44 ± 1.82f
Note: pooled data from three independent experiments; 900 cells were analyzed per dose; 3 animals were used for each treatment. Values with
same superscripts are not signiﬁcant (p> 0.05); values with different superscripts are signiﬁcantly different from one another (p< 0.05)
according to Duncan Post hoc test.
Table 4 Percentage frequency of chromosomal aberrations (mean ± SE) induced by conditioning, challenging and combined doses of
MMS in non diabetic and diabetic mice bone marrow cells recovered after 48 h.
Treatments Chromosomal aberrations Total aberrations
Chromatid aberrations Chromosomal aberrations
Control Non diabetic 2.22 ± 0.31 0 2.22 ± 0.31a
Diabetic 2.33 ± 0.29 0.11 ± 0.11 2.44 ± 0.4a
Conditioning Non diabetic 17.00 ± 1.35 1.00 ± 0.58 18.00 ± 0.96b
Diabetic 11.00 ± 1.69 0.78 ± 0.11 11.78 ± 0.59ab
Challenging Non diabetic 50.89 ± 2.78 10.00 ± 2.83 71.33 ± 9.51c
Diabetic 44.33 ± 3.29 8.56 ± 2.20 52.89 ± 1.46d
Combined Non diabetic 36.00 ± 2.65 4.33 ± 1.82 40.33 ± 0.67fe
Diabetic 34.33 ± 2.98 3.44 ± 1.44 37.78 ± 1.22e
Note: pooled data from three independent experiments; 900 cells were analyzed per dose; 3 animals were used for each treatment. Values with
same superscripts are not signiﬁcant (p> 0.05); values with different superscripts are signiﬁcantly different from one another (p< 0.05)
according to Duncan Post hoc test.
Table 5 Percentage frequency of chromosomal aberrations (mean ± SE) induced by conditioning, challenging and combined doses of
MMS in non diabetic and diabetic mice bone marrow cells recovered after 72 h.
Treatments Chromosomal aberrations Total number of aberrations
Chromatid aberrations Chromosomal aberrations
Control Non diabetic 2.22 ± 0.31 0 2.22 ± 0.31a
Diabetic 2.33 ± 0.44 0.11 ± 0.11 2.44 ± 0.4a
Conditioning Non diabetic 13.44 ± 1.13 0.67 ± 0.33 14.11 ± 1.06b
Diabetic 9.66 ± 1.36 0.44 ± 0.29 10.11 ± 0.78b
Challenging Non diabetic 39.22 ± 2.86 9.56 ± 1.75 48.11 ± 1.55d
Diabetic 31.67 ± 3.17 4.11 ± 2.26 35.78 ± 0.59e
Combined Non diabetic 32.00 ± 2.85 3.67 ± 1.91 35.67 ± 1.86e
Diabetic 27.00 ± 2.22 3.44 ± 1.74 30.44 ± 0.78f
Note: pooled data from three independent experiments; 900 cells were analyzed per treatment; 3 animals were used for each treatment. Values
with same superscripts are not signiﬁcant (p> 0.05); values with different superscripts are signiﬁcantly different from one another (p< 0.05)
according to Duncan Post hoc test.
Cytogenetic adaptive response 205Olsson and Lindahl [34] demonstrated that ada coded methyl-
transferase, transfers the ethyl group of O6-ethylguanine at a
rate of 10 times less efﬁcient than that for the methyl transfer.In wild-type E. coli, the adaptive response began to contribute
to O6-methylguanine repair about one hour after alkylation,
which is the time required for full induction of the ada DNA
Table 6 Percentage reduction of chromosomal breaks (mean ± SE) after combined treatment of EMS at different recovery times in
bone marrow cells of non diabetic and diabetic mouse.
RT in hours EMS Additive eﬀect A Combined eﬀect B Reduction of chromosomal breaks Reduction in (%) C
24 Non diabetic 1.39 ± 0.11 0.71 ± 0.04 0.68 ± 0.07 49.04 ± 1.19
Diabetic 0.95 ± 0.05 0.57 ± 0.04 0.38 ± 0.07 40.00 ± 6.07
48 Non diabetic 1.05 ± 0.08 0.62 ± 0.02 0.43 ± 0.07 40.82 ± 4.13
Diabetic 0.73 ± 0.04 0.47 ± 0.03 0.26 ± 0.02 35.01 ± 2.47
72 Non diabetic 0.90 ± 0.06 0.53 ± 0.04 0.37 ± 0.02 41.33 ± 1.28
Diabetic 0.62 ± 0.05 0.39 ± 0.02 0.23 ± 0.03 36.90 ± 1.57
Note: percentage of reduction was calculated using formula C= 100  (B/A * 100).
Table 7 Reduction (%) of chromosomal breaks (mean ± SE) after combined treatment of MMS at different recovery times in bone
marrow cells of non diabetic and diabetic mouse.
RT in hours MMS Additive eﬀect A Combined eﬀect B Reduction of chromosomal breaks Reduction in (%) C
24 Non diabetic 1.46 ± 0.06 0.59 ± 0.03 0.87 ± 0.03 59.59 ± 0.63
Diabetic 1.04 ± 0.04 0.5 ± 0.01 0.54 ± 0.03 51.74 ± 1.38
48 Non diabetic 0.91 ± 0.04 0.45 ± 0.01 0.46 ± 0.03 50.92 ± 1.37
Diabetic 0.75 ± 0.02 0.41 ± 0.02 0.34 ± 0.02 45.13 ± 1.30
72 Non diabetic 0.73 ± 0.02 0.39 ± 0.01 0.34 ± 0.03 46.36 ± 2.67
Diabetic 0.51 ± 0.01 0.35 ± 0.01 0.16 ± 0.01 32.03 ± 1.97
Note: percentage of reduction was calculated using formula C= 100  (B/A * 100).
206 B.B.D. Khalandar, V. Vasudevmethyltransferase. In contrast, the adaptive response did not
play such a large role in the repair of O6-ethylguanine and
O4-ethylthymine, because ethylation of DNA is a poor inducer
of the adaptive response. Contrary to this Mahmood and
Vasudev [29] and Vasudev et al. [37] has demonstrated
ethylating agents as efﬁcient inducer of adaptive response than
methylating agents in P. pictus i.e. insect system. Hence, further
understanding of this phenomenon is needed using different
alkylating agents and varied test systems.
It is worthy to note in the present investigations that there
is an increased chromosomal break with combined treatment
of both the tested agents in diabetic mouse compared to non
diabetic mouse (Tables 1–5). Thus it is hypothesized that adap-
tive response is not efﬁciently induced by tested agents in dia-
betic mouse than that of non diabetic. This is the ﬁrst report in
the literature and hence further proof is required to decipher
the same with some more experiments. However, it can be
mentioned here that, Blasiak et al. [38] when treated lympho-
cytes of healthy and diabetic patients with hydrogen peroxide
or doxorubicin and incubated with three different repair
enzymes such as endonuclease III, formamidopyrimidine-
DNA glycosylase and 3-methyladenine-DNA glycosylase II,
showed decreased DNA repair in diabetic compared to con-
trol. Simone et al. [39] have also demonstrated the decreased
expression of 8-oxo G-DNA glycosylase (OGG), a DNA
repair enzyme, in kidney of diabetic rats and Akcay et al.
[40] of O-6 methyl guanine methyltransferase (MGMT)
activity in leukocytes of diabetic patients.
Studies have revealed that the adaptive response is mani-
fested up to the third mitosis, and later due to dilution of
the repair system as the cells divide into subsequent cell cycles,there is vanishing of adaptive response [41,42]. It is further
strengthened by the observations of Mahmood et al. [25],
Harish et al. [43], Guruprasad and Vasudev [44], Guruprasad
et al. [36], where they have shown the reduction in frequency
of chromosomal aberrations at 72 h RT, i.e. third subsequent
mitosis in normal mouse bone marrow cells compared to
24 h and 48 h RTs. The present investigations are also on
par with the earlier results in that the percentage reduction
of chromosomal breaks with combined treatment of MMS is
decreased from 51.74% at 24 h to 32.03% at 72 h RT in
diabetic mouse, similar observations were made with EMS
also (Tables 6 and 7). Similarly it can also be noted that the
lowest breaks were seen at 72 h than at 24 and 48 h RTs,
induced by conditioning and challenging doses of both
the tested agents (Fig. 1). This agrees with earlier reports of
Obe and Beek [45], where it has been amply proved that the
decrease in aberration frequency with increasing culturing time
reﬂects a mechanism of mitotic selection of aberration bearing
cells.
In conclusion, it can be stated that (1) both EMS and MMS
induced adaptive response not only in non diabetic mouse but
also in diabetic mouse. (2) Further, decrease in chromosomal
breaks in diabetic mouse compared to non diabetic indicated
reduced reparability in diabetic mice. (3) And also ethylating
and methylating agents showed differential adaptive response
to chromosome damages in diabetic mice.
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